LYT-100 employs a multimodal mechanism of action to potentially reduce, delay or prevent the lung dysfunction documented in COVID-19 patients More: PureTech advances experimental COVID-19 drug into global trials Source: News
read moreResearchers are hopeful that this ‘ground-breaking approach’ could accelerate the prediction of which patients are more at risk of their disease returning More: Researchers develop AI tool able to predict cancer relapse Source: News
read moreThe drug giant agreed a new price for Tecentriq with NHS England and Improvement More: NICE u-turn backs Roche's Tecentriq for small-cell lung cancer Source: News
read moreWant COVID-19 herd immunity? Get 40% of population vaccinated, says ex-FDA chief Gottlieb aliu Wed, 05/27/2020 – 12:08 More: Want COVID-19 herd immunity? Get 40% of population vaccinated, says ex-FDA chief Gottlieb Source: fierce
read moreWhat’s needed to prove a COVID-19 vaccine works—and are top players across 3 continents there yet? aliu Wed, 05/27/2020 – 10:50 More: What's needed to prove a COVID-19 vaccine works—and are top players across 3 continents there yet? Source: fierce
read moreNovavax snares $167M buyout to rapidly scale up COVID-19 vaccine manufacturing kblankenship Wed, 05/27/2020 – 10:04 More: Novavax snares 7M buyout to rapidly scale up COVID-19 vaccine manufacturing Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals